Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVGH quadrivalent Pan-Salmonella vaccine with and without alum in healthy young adults
PACTR202605582528470Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of Pan-Salmonella vaccine in nontyphoidal salmonellosis, typhoid fever and paratyphoid fever, sponsored by GSK. Primary endpoint: Safety and reactogenicity of GVGH Pan-Salmonella vaccine. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Pan-Salmonella vaccine
03
Conditions
nontyphoidal salmonellosistyphoid feverparatyphoid fever
Beyond the preview
Go deeper on PACTR202605582528470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605582528470.